The patient was commenced on BRAF-targeted therapy in the form of the BRAF inhibitor encorafenib in combination with the MEK inhibitor binimetinib. MRI of the brain 3 months post-initiation of BRAF-targeted therapy demonstrated interval reduction in the size of the cystic tumor lesions in the right basal ganglia and midbrain suggestive of treatment response (see Figure 6). This evidence concerns the gene BRAF and cystic neoplasm.